Kuchyne na miru

Pharmaceutical Executive September 2018

September 2018 | Volume 38, Issue 9
Pharmaceutical Executive September 2018
Issue PDF
By Pharmaceutical Executive Editors
Click the title above to open the Pharmaceutical Executive September 2018 issue in an interactive PDF format.
From the Editor
In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.
Pharm Exec talks with CSL's top executive about the realities of running the global, Australian-headquartered specialty biotech company.
While definitions for “specialty drug” vary, this once-niche treatment market may be poised to steer the future of prescription medicine and patient care.
Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.
With specialty companies getting smarter in applying their big data insights to product marketing, the true commercial potential of machine learning and predictive modeling may soon be within reach.
How one nonprofit and its out-front leader are joining forces with industry to advance a new personalized medicine approach for cystic fibrosis patients with nonsense mutations.
How low-cost drugs can succeed in the specialty pharmacy channel, by Charlie Bell.
Pharm Exec’s latest company leaderboard in delivering shareholder value highlights the most critical measure of management performance—return on invested capital.
New Action Plan aims to streamline development, but rebates and reimbursement block market access.
How industry can benefit from this new view on innovation.
Special Sponsored Section
Faced with looming uncertainties triggered by the upcoming Brexit, the United Kingdom’s life sciences sector, which constitutes one of the last big remaining bastions of British industry, is not about to rest on its laurels.


lorem ipsum